Xtant Medical (NYSEAMERICAN:XTNT) Price Target Cut to $1.00 by Analysts at BTIG Research

Xtant Medical (NYSEAMERICAN:XTNT) had its price target lowered by BTIG Research from $1.50 to $1.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock.

Separately, Craig Hallum reaffirmed a “buy” rating on shares of Xtant Medical in a research report on Wednesday, March 18th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $1.00.

Xtant Medical Stock Performance

NYSEAMERICAN:XTNT opened at $0.56 on Tuesday. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $78.12 million, a price-to-earnings ratio of 55.86 and a beta of -0.30. The firm’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $0.67. Xtant Medical has a twelve month low of $0.34 and a twelve month high of $0.95.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings results on Tuesday, March 31st. The medical device company reported $0.03 earnings per share (EPS) for the quarter. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.The firm had revenue of $32.36 million during the quarter, compared to the consensus estimate of $30.75 million.

Institutional Investors Weigh In On Xtant Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XTNT. Crescent Grove Advisors LLC lifted its holdings in Xtant Medical by 94.3% in the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after buying an additional 200,000 shares in the last quarter. Jane Street Group LLC purchased a new position in Xtant Medical in the 2nd quarter valued at about $26,000. Nantahala Capital Management LLC grew its stake in shares of Xtant Medical by 500.3% during the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after acquiring an additional 57,000,000 shares in the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Xtant Medical during the second quarter worth about $4,875,000. Finally, Mink Brook Asset Management LLC increased its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after acquiring an additional 60,997 shares during the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Trending Headlines about Xtant Medical

Here are the key news stories impacting Xtant Medical this week:

• Positive Sentiment: Strong FY2025 results: full-year revenue of $133.9M (up 14% YoY), positive net income, adjusted EBITDA and operating cash flow; $17.3M cash on hand plus $10.5M received after year-end tied to a divestiture. Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Q4 beat / strong revenue growth highlighted on the earnings call — underlying operating performance was solid, which supports longer-term recovery if management navigates the divestiture impact. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Analyst stance: BTIG cut its price target from $1.50 to $1.00 but kept a “buy” rating, signaling continued analyst conviction in upside despite lower near-term guidance. BTIG Research note (Benzinga)
• Neutral Sentiment: Full earnings call transcript available for investors wanting granular detail on revenue drivers, divestiture timing and margin outlook. Earnings Call Transcript
• Negative Sentiment: 2026 guidance trimmed: management outlined a $95M–$99M revenue outlook for 2026, explicitly citing the Companion Spine divestiture and the expiration/roll-off of Q-code license revenue — this guidance is the primary reason shares moved lower. Xtant outlines $95M-$99M 2026 revenue outlook
• Negative Sentiment: Immediate market reaction: reports note shares fell following the weak 2026 outlook despite the quarter beat, reflecting investor concern over near-term revenue headwinds. Xtant shares drop nearly 5%
• Negative Sentiment: Short interest rising: data show a notable increase in short interest, which can add downward pressure or increase volatility until visibility on 2026 revenue improves. Sees Large Growth in Short Interest

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.